News | Interventional Radiology | April 10, 2019

Ethicon Launches Global Liver Lesion Ablation Registry

Multicenter observational registry will collect real-world data from 1,500 patients who have liver lesions ablated with Ethicon’s Neuwave Microwave Ablation System

Ethicon Launches Global Liver Lesion Ablation Registry

April 10, 2019 – Johnson & Johnson Medical Devices Companies announced Ethicon has launched a new global registry to collect and analyze real-world data on patients with soft tissue liver lesions ablated with the company’s Neuwave Microwave Ablation System. The company made the announcement at the annual meeting of the Society of Interventional Radiology (SIR 2019), March 23-28 in Austin, Texas.

The multicenter, observational registry will follow approximately 1,500 patients worldwide for a total of five years from the date of their first liver ablation procedure with the Neuwave System. The minimally invasive microwave ablation technology uses heat transmitted through image-guided needle-like probes to destroy soft tissue lesions.

Real-world data will be collected from up to 30 centers throughout the world on the technical aspects of the procedure including ablation time under varying liver tissue and lesion conditions. Efficacy and other outcome data will also be documented and assessed at various time points over the course of the study.

“The goal of the registry is to systematically and comprehensively develop ablation parameter guidance for the microwave ablation of liver lesions with the Neuwave System,” said Paul Laeseke, M.D., Ph.D., interventional radiologist, University of Wisconsin School of Medicine and Public Health, who consulted on the design of the registry. “Microwave ablation is an important treatment option that is increasingly being utilized throughout the world, and this data may provide new insights into factors that are critical for successful outcomes across a range of patients, clinical settings and health care providers. The registry will be an important contribution to our understanding of microwave ablation and support its further adoption.”

The registry will also include data from consenting patients enrolled in other Ethicon-sponsored studies on microwave liver ablation with the Neuwave System in Korea and China, and a multicenter study that is evaluating the device using Neuwave’s Ablation Confirmation Software, which helps physicians identify ablation targets, assess appropriate probe placement and confirm the technical success of each procedure.

For more information: www.ethicon.com

Related Content

Henry Ford Hospital's ViewRay MRIdian linear accelerator system allows real-time MRI-guided radiotherapy. Shown is the support staff for this system. In the center of the photo is Benjamin Movsas, M.D., chair of radiation oncology at Henry Ford Cancer Institute. Second from the right is Carrie Glide-Hurst, Ph.D., director of translational research, radiation oncology.

Henry Ford Hospital's ViewRay MRIdian linear accelerator system allows real-time MRI-guided radiotherapy. Shown is the support staff for this system. In the center of the photo is Benjamin Movsas, M.D., chair of radiation oncology at Henry Ford Cancer Institute. Second from the right is Carri Glide-Hurst, Ph.D., director of translational research, radiation oncology.

Feature | Henry Ford Hospital | May 21, 2019 | Dave Fornell, Editor
Henry Ford Hospital thought leaders regularly speak at the radiation oncology and radiology conferences about new res
Philips Launches IntraSight Interventional Applications Platform
Technology | Interventional Radiology | May 20, 2019
Philips announced the launch of the new IntraSight interventional applications platform. The secure, application-based...
Netherlands Hospital to Install State-of-the-Art MRI Ablation Center
News | Magnetic Resonance Imaging (MRI) | May 13, 2019
Imricor announced the signing of a commercial agreement with the Haga Hospital in The Hague, Netherlands to outfit a...
Clinical Trial Explores Opening Blood-Brain Barrier in Fight Against Alzheimer's

Vibhor Krishna, M.D., (right) fits David Shorr with a helmet-like device used in a new clinical trial for Alzheimer’s disease at The Ohio State University Wexner Medical Center. The device uses MRI-guided imaging to deliver focused ultrasound to specific areas of the brain to open the blood-brain barrier. Image courtesy of Ohio State University Wexner Medical Center.

News | Focused Ultrasound Therapy | May 09, 2019
May 9, 2019 — A new clinical trial at The Ohio State University Wexner Medical Center and two other sites is testing
Ultrasonic Device Safe and Effective for Lung Vessel Sealing in Minimally Invasive Lobectomy
News | Interventional Radiology | May 06, 2019
According to a new study, an ultrasonic vessel-sealing device can improve patient outcomes by reducing the incidence of...
360 degree view inside an Interventional radiology lab at Henry Ford Hospital used for neuro-interventions and stroke.
360 Photos | 360 View Photos | May 06, 2019
This is a 360 degree photo view inside the neuro-interventional radiology lab at ...
Multisociety Position Statement Endorses Prostatic Artery Embolization
News | Interventional Radiology | May 02, 2019
A new position statement from interventional radiology professional societies in the U.S. and Europe states that...
Mentice and RAD-AID Collaborate to Improve Access to Interventional Radiology in Resource-constrained Regions
News | Interventional Radiology | April 22, 2019
April 22, 2019 — Mentice AB, provider of endovascular performance solutions, has signed an agreement with the nonprof